Boughton Soleil, Chief Legal Officer, has demonstrated a consistent pattern of selling activity in HIMS & Hers Health, Inc. (HIMS) shares, as reflected in SEC Form 4 filings. Over 34 reported transactions, Soleil has exclusively sold shares, with no recorded purchases, resulting in a total sell value of $7,848,143.65. This trend has persisted into recent months, with eight sales executed between September 2025 and March 2026. Notably, Soleil’s largest transactions occurred on March 13, 2026, with sales valued at $549,225.21 and $3,630,712.29, alongside smaller sales on March 17, 2026, totaling $118,808.28. Earlier sales in 2025 ranged from $92,663.82 to $155,029.23, indicating a steady divestment strategy.
The transactions primarily involve shares acquired through derivative securities, including exercises of options and awards, as denoted by transaction codes “M” and “F.” Soleil’s activity is concentrated solely in HIMS, reflecting a singular focus on this company. The absence of buying activity suggests a deliberate reduction in equity exposure rather than a rebalancing of holdings. This pattern aligns with Soleil’s role as Chief Legal Officer, though the filings do not provide insight into the rationale behind the transactions. The data underscores a clear and sustained selling bias, with significant liquidity events in early 2026 marking the culmination of this trend.
AI-assisted summary